公开(公告)号：US20210244880A1

公开(公告)日：2021-08-12

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Trang LY ,  Yibin ZHENG ,  Connor GULLIFER ,  Kyle GROVER

IPC: A61M5/172 ,  G16H20/17

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.

公开(公告)号：US20240299660A1

公开(公告)日：2024-09-12

申请号：US18667224

申请日：2024-05-17

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Trang LY ,  Yibin ZHENG ,  Connor GULLIFER ,  Kyle GROVER

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/07 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2230/201

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.